← All trials
NCT05275725
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 12, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Mar 11, 2022
- Last posted
- Aug 15, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McGill UniversityLead sponsor
- McGill UniversitySponsor investigator
- Saint Francis Memorial HospitalCollaborator
- WalimuCollaborator
- Kawempe National Referral HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.